Navigation Links
ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA
Date:1/19/2011

tential for the FDA to impose other requirements to be completed before or after approval of the Exelbine NDA, including that the FDA may require ADVENTRX to perform additional nonclinical, bioequivalence or clinical studies; ADVENTRX's reliance on third parties to assist with its bioequivalence trials, regulatory submissions, manufacturing and other important aspects of the Exelbine development program, and the risk that FDA approval may be delayed if their performance is found to have been substandard; the risk that any patent issued to ADVENTRX may not provide sufficient protection and market exclusivity for Exelbine and may be challenged, invalidated, infringed or circumvented by third parties, including by ADVENTRX's competitors; ADVENTRX's dependence on the success of Exelbine as its first product candidate to be submitted for regulatory approval; the potential that ADVENTRX may require substantial additional funding to obtain FDA approval for and commercialize Exelbine, and the risks inherent in these activities; the potential for ADVENTRX to enter into a commercial partnership or other strategic transaction relating to Exelbine and that such partnership or transaction may not succeed in commercializing Exelbine; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov.  

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014  The law firm McElroy, ... that it will serve as host for "Show ... the Risks of Healthcare Reform," a one-day conference ... delivery systems, reimbursement, compliance and enforcement in a ... Logo -  http://photos.prnewswire.com/prnh/20140916/146606 Logo -  ...
(Date:9/17/2014)... and LEIPZIG, Germany ... announced that it has entered into an exclusive ... development of antibody-based imaging agents to image CD4+ ... collaboration with Novotectid expands ImaginAb,s capability to precisely diagnose ... and autoimmune disease areas. The ability to image ...
(Date:9/17/2014)... LAWRENCEVILLE, N.J. , Sept. 17, 2014 /PRNewswire-USNewswire/ ... that details how to implement GS1 Standards to ... (DSCSA), and enhance patient safety and security in ... Applying GS1 Standards to U.S. Pharmaceutical Supply ... Chain Security Act , was developed in ...
Breaking Medicine Technology:Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2ImaginAb Expands ImmunoPET Pipeline to Include CD4+ T-Cell Imaging 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4
(Date:9/17/2014)... Rochelle, NY, September 17, 2014Diffusion Tensor Imaging (DTI), ... detects microstructural changes in brain tissue, can help ... outcomes following mild traumatic brain injury compared to ... according to a new study published in ... Mary Ann Liebert, Inc., publishers . The ...
(Date:9/17/2014)... CORVALLIS, Ore. People with facial paralysis are perceived ... in the universal language of facial expression, a new ... , The findings highlight the important role the ... hold a prejudice against those with facial paralysis because ... of psychology in the College of Liberal Arts at ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Fasoo ... Security Testing (SAST) tool, at AppSec USA 2014 in ... 9 am to 6 pm at booth G4 inside ... of the leading software security conferences for developers, auditors, ... tool that provides developers and managers with the ability ...
(Date:9/17/2014)... Elsevier, a world-leading provider of scientific, technical and ... publication of a position statement by the European ... Maturitas on the topic of breast ... prevalent cancer in women, with slightly more than ... Mammography screening is a well-established method to detect ...
(Date:9/17/2014)... September 17, 2014 In ongoing ... Inc.’s Drug Benefit News (DBN) continues to find ... in its Aug. 8 issue , CVS Caremark ... lists for 2015 each cut more drugs than ... savings these exclusions are likely to achieve. Despite ...
Breaking Medicine News(10 mins):Health News:New MRI technique helps clinicians better predict outcomes following mild traumatic brain injury 2Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 2Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 3Health News:Fasoo to Introduce Their Testing Tool to Improve Software Security and Quality at AppSec USA 2014 2Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 2Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 3
... Netherlands / Rockville, MD, USA (September 22, 2010) ... Exchange: CRX) and the Aeras Global TB Vaccine Foundation ... trial in infants of the jointly developed tuberculosis (TB) ... of the trial is to test the safety and ...
... of Cincinnati (UC) researcher will receive $2.5 million over ... (NIDA) to support his work on a potential immunotherapy ... in the psychiatry and behavioral neuroscience department, is one ... Awards for Innovative Medication Development Research. Award winners receive ...
... HealthDay Reporter , TUESDAY, Sept. 21 (HealthDay ... suicide rates appear to be highest among residents of ... fresh research points to a possible explanation: high altitudes. ... and the high prevalence of gun ownership, may contribute ...
... therapies against cancer to be effective, scientists need to ... makes a cancer cell resistant to a drug and ... Lombardi Comprehensive Cancer Center and Fox Chase Cancer Center. ... , the investigators discuss how cancer cells activate a ...
... of Rhode Island Hospital, is the recipient of the ... Imaging Network (ACRIN). Dupuy received the award for leading ... (RFA) to reduce the pain of osseous metastases (cancer ... scientific paper published during the previous year that stands ...
... Physicians now have access to real time radiology ... Viewbox (patent pending) is a portable interface system ... specialist consultation to physicians using any internet-ready device. ... in transmitting patient information and offers a timely ...
Cached Medicine News:Health News:Aeras and Crucell announce Phase II clinical trial start in Kenya 2Health News:Aeras and Crucell announce Phase II clinical trial start in Kenya 3Health News:Aeras and Crucell announce Phase II clinical trial start in Kenya 4Health News:Researcher wins $2.5 million award from National Institute on Drug Abuse 2Health News:Is High Altitude Linked to Suicide Risk? 2Health News:Is High Altitude Linked to Suicide Risk? 3Health News:Targeted therapy triggers complex mechanism of resistance 2Health News:Targeted therapy triggers complex mechanism of resistance 3Health News:Targeted therapy triggers complex mechanism of resistance 4Health News:Rhode Island Hospital physician receives national award for research 2Health News:Virtual Viewbox offers portable radiology access for physicians 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: